Research
Hormonal
Aging is associated with impaired glucose tolerance due to reduced insulin sensitivity and failure of insulin secretion to compensate, without changes in basal glucose or insulin-independent glucose disposal.
As you age, your body's ability to handle sugar after meals (glucose tolerance) declines due to insulin resistance and insufficient insulin response, but your fasting blood sugar may remain normal. This highlights the importance of monitoring post-meal glucose in older adults.
GoodQualifiesHIGH confidence
aging was associated with a >60% reduction in insulin sensitivity index with no compensatory increase of glucose-induced insulin secretion... In contrast, neither basal glucose nor GE (measured as Sg in the minimal model) was altered.
Why this rating
Based on human cross-sectional and longitudinal studies (Chen et al., Kahn et al.).
Source
Distinct Roles for Brain and Pancreas in Basal and Postprandial Glucose Homeostasis
Kimberly M. Alonge et al. · Diabetes · 2023
DOI 10.2337/db22-0969
narrative_reviewCited 12×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Basal glucose homeostasis is governed by insulin-independent mechanisms primarily regulated by the brain, whereas glucose tolerance is determined by the interaction between insulin secretion and insulin sensitivity.Good
- Central administration of leptin or FGF1 can reverse basal hyperglycemia in diabetic animal models through insulin-independent mechanisms, without improving glucose tolerance.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →